# **Resource Summary Report**

Generated by dkNET on Apr 25, 2025

# **SeqGSEA**

RRID:SCR\_005724

Type: Tool

### **Proper Citation**

SeqGSEA (RRID:SCR\_005724)

#### **Resource Information**

**URL:** http://bioconductor.org/packages/devel/bioc/html/SeqGSEA.html

**Proper Citation:** SegGSEA (RRID:SCR\_005724)

**Description:** Software package that provides methods for gene set enrichment analysis of high-throughput RNA-Seq data by integrating differential expression and splicing. It uses negative binomial distribution to model read count data, which accounts for sequencing biases and biological variation. Based on permutation tests, statistical significance can also be achieved regarding each gene"s differential expression and splicing, respectively.

**Abbreviations:** SeqGSEA

Synonyms: SeqGSEA - Gene Set Enrichment Analysis (GSEA) of RNA-Seq Data:

integrating differential expression and splicing

Resource Type: data analysis software, software resource, data processing software,

software application

**Keywords:** differential expression, gene expression, gene set enrichment, rna-seq,

sequencing, splicing

**Funding:** 

Availability: GNU General Public License, v3 or newer

Resource Name: SeqGSEA

Resource ID: SCR 005724

Alternate IDs: OMICS\_02251

**Record Creation Time:** 20220129T080232+0000

Record Last Update: 20250425T055450+0000

### Ratings and Alerts

No rating or validation information has been found for SeqGSEA.

No alerts have been found for SeqGSEA.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We found 31 mentions in open access literature.

**Listed below are recent publications.** The full list is available at dkNET.

Qiu L, et al. (2024) TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis. EMBO molecular medicine, 16(5), 1193.

Vellky JE, et al. (2024) ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature. Clinical cancer research: an official journal of the American Association for Cancer Research, 30(8), 1530.

Lio CT, et al. (2024) Comprehensive benchmark of differential transcript usage analysis for static and dynamic conditions. bioRxiv: the preprint server for biology.

Guan X, et al. (2024) Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer. Clinical and translational medicine, 14(6), e1692.

Balcioglu O, et al. (2024) Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation. NPJ breast cancer, 10(1), 80.

Xu P, et al. (2024) Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nature communications, 15(1), 6626.

Balcioglu O, et al. (2024) Mcam stabilizes luminal progenitor breast cancer phenotypes via Ck2 control and Src/Akt/Stat3 attenuation. bioRxiv: the preprint server for biology.

Jalnapurkar SS, et al. (2024) PHF6 suppresses self-renewal of leukemic stem cells in AML. bioRxiv: the preprint server for biology.

Pichavaram P, et al. (2024) Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis. Molecular cancer therapeutics, 23(4), 478.

Hu L, et al. (2024) The CDK4/6 Inhibitor Palbociclib Synergizes with ATRA to Induce Differentiation in AML. Molecular cancer therapeutics, 23(7), 961.

Zhu X, et al. (2024) Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors. Cancer research, 84(1), 84.

Steinkamp MP, et al. (2023) Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity. Cancer research communications, 3(2), 309.

Yang Z, et al. (2023) Unraveling the molecular links between benzopyrene exposure, NASH, and HCC: an integrated bioinformatics and experimental study. Scientific reports, 13(1), 20520.

Mehdi A, et al. (2023) S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas. Neoplasia (New York, N.Y.), 36, 100874.

Gopal RK, et al. (2023) Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma. Cancer discovery, 13(8), 1904.

Xu P, et al. (2023) Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. Pharmacological research, 189, 106692.

Carney SV, et al. (2023) Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance. Clinical cancer research: an official journal of the American Association for Cancer Research, 29(9), 1763.

Li X, et al. (2023) Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6+ CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma. Frontiers in oncology, 13, 1099385.

Liu X, et al. (2022) Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Nature cancer, 3(7), 866.

Deng H, et al. (2022) Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung

cancer by inducing mtDNA damage. Cellular and molecular life sciences : CMLS, 79(8), 445.